The 340B Drug Pricing Program has a dirty little secret: drug manufacturer rebates intended to help poor patients access healthcare services are being used to fund excessive compensation for hospital CEOs. This program was designed to help patients, not pad the pockets of healthcare executives. This system is failing them! Patients are starting to ask the question: Is the 340B Program the Next ‘Too Big to Fail’?